Abstract:10553 Background: Cancer-specific therapy requires the identification of the tumor origin. Detecting cancer and identifying the tumor origin in early stage can improve the survival and prognosis of cancer patients. However, early diagnosis of cancer is challenging as the early symptoms of cancer are mild or even absent. In order to improve the diagnostic efficacy and the patient compliance, we developed a two-stage model for cancer diagnosis and tissue of origin (TOO) classification, using DNA methylation profile evaluated through non-invasive blood-based testing as biomarker. Methods: cfDNA samples from 302 healthy and 598 cancer patients of 8 cancer types (colorectal, lung, liver, pancreatic, gastric, esophagus, breast and ovarian) were sequenced by our in-house-designed DNA methylation panel and randomly split into a training dataset (213:426) and a testing dataset (89:172). The testing dataset was reserved to evaluate the performance of models and would not be used during the feature selection and model development process. Methylation levels of cfDNA samples were measured by the methylated fragment ratios (MFRs) in methylated-correlated blocks (MCBs). We first selected pan-cancer markers by comparing the MFR values of MCBs between the healthy and the diseased individuals and developed a binary classifier (hyper-methylation score). Sample correctly predicted by the hyper-methylation score in the cancer group were then used for TOO marker selection and model fitting. TOO biomarkers were obtained by a series of pairwise comparisons of MFR values between any two cancer types. A deconvolution model was built to estimate the composition of ctDNA, which implied the tumor origin. Results: The hyper-methylation score model based on 135 MCB biomarkers achieved an area under the curve (AUC) of 0.89 in the training dataset and 0.85 in the testing dataset. Under a specificity of 94.8%, sensitivity was 66.2% in the training dataset. Using the 282 cases successfully being predicted, 583 TOO markers were selected to build the deconvolution model. In the testing dataset, the specificity was 95.5%, and the overall sensitivity was 66.3%. With increasing stage, sensitivity increased in all cancer types: 34.6%, 57.1%, 62.5% and 84.8% in stage I, II, III and IV respectively. In stage I-III, sensitivity was 52.3%. TOO classes were predicted in the 114 true positives from the hyper-methylation score model, producing a top 1 accuracy (true class matched the most probable class) of 75.4% and a top 2 accuracy (true class matched the first or the second most probable class) of 84.2%. Top 1 accuracy was 71.1% in stage I-III, vs. 84.0% in stage IV. Top 2 accuracy was 82.2% in stage I-III, vs. 90.0% in stage IV. Conclusions: Our cfDNA-based epigenetic method achieved outstanding performance either in pan-cancer detection or in TOO classification, and is a promising tool for early-stage cancer diagnosis.

Identification of FUT7 hypomethylation as the blood biomarker in prediction of early-stage lung cancer

Early detection of lung cancer using a panel of circulating cell-free DNA methylation biomarkers.

FYB Methylation in Peripheral Blood As a Potential Marker for the Early-Stage Lung Cancer: a Case-Control Study in Chinese Population

Novel Blood-Based Hypomethylation of SH3BP5 is Associated with Very Early-Stage Lung Adenocarcinoma.

Accurate detection of early-stage lung cancer using a panel of circulating cell-free DNA methylation biomarkers

Whole-genome DNA methylation and DNA methylation-based biomarkers in lung squamous cell carcinoma

Integrative Analysis of DNA Methylomes Reveals Novel Cell-Free Biomarkers in Lung Adenocarcinoma.

Blood FOLR3 methylation dysregulations and heterogeneity in non-small lung cancer highlight its strong associations with lung squamous carcinoma

5-Hydroxymethylome in Circulating Cell-free DNA as A Potential Biomarker for Non-small-cell Lung Cancer

Integrated 5-hydroxymethylcytosine and fragmentation signatures as enhanced biomarkers in lung cancer

Discovery and validation of methylation signatures in blood-based circulating tumor cell-free DNA in early detection of colorectal carcinoma: a case-control study

An ultrasensitive approach for cancer screening and tissue of origin prediction based on targeted methylation sequencing of cell-free DNA.

A Highly Sensitive and Specific Non‐Invasive Test through Genome‐Wide 5‐Hydroxymethylation Mapping for Early Detection of Lung Cancer

A prognostic 11-DNA methylation signature for lung squamous cell carcinoma

A Fragment-Based Algorithm for Identifying Pan-Cancer Differential Methylation Markers from Cfdna.

Lung cancer scRNA-seq and lipidomics reveal aberrant lipid metabolism for early-stage diagnosis

Identification and Validation of the Methylation Biomarkers of Non-Small Cell Lung Cancer (NSCLC).

Development of a Noninvasive Method for Early Stage Lung Cancer Diagnosis Based on Methylation Analysis of SHOX2 and PTGER4

Diagnostic signatures for lung cancer by gut microbiome and urine metabolomics profiling.

Comparison of tumor and two types of paratumoral tissues highlighted epigenetic regulation of transcription during field cancerization in non-small cell lung cancer

A Diagnostic Panel of DNA Methylation Biomarkers for Lung Adenocarcinoma